Trial Profile
Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2022
Price :
$35
*
At a glance
- Drugs MG56 (Primary) ; MG56 (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Inmunotek
- 10 Nov 2021 Status changed from recruiting to completed.
- 12 Jun 2020 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 12 Jun 2020 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.